Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 6125

Drug Profile

RG 6125

Alternative Names: RG6125; SDP-051

Latest Information Update: 21 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adheron Therapeutics
  • Developer Adheron Therapeutics; Roche
  • Class Antifibrotics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Osteoblast cadherin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Non-alcoholic steatohepatitis; Rheumatoid arthritis

Most Recent Events

  • 12 Jun 2019 Efficacy, pharmacokinetic and adverse events data from a phase II trial in Rheumatoid Arthritis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
  • 17 Oct 2018 Discontinued - Phase-II for Rheumatoid arthritis in USA (Parenteral) (Roche pipeline, October 2018)
  • 17 Oct 2018 Discontinued - Preclinical for Cancer in USA (Parenteral) (Roche pipeline, October 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top